Technology | Treatment Planning | November 20, 2015

GE Introduces Accuracy for Radiation Therapy Planning with Discovery RT

CT simulator introduced at ASTRO offers improved planning for oncology patients

GE Healthcare, Discovery RT, CT simulation, radiation therapy, treatment planning, RSNA 2015, ASTRO 2015

Image courtesy of GE Healthcare

November 20, 2015 — GE Healthcare introduced the Discovery RT, a new advanced radiation therapy planning computed tomography (CT) system at the 57th annual American Society for Radiation Oncology (ASTRO) meeting in San Antonio, Texas, Oct. 18-21.

Discovery RT is a CT simulator that that enables flexible patient positioning, software to address challenges presented by patient motion and metal, precise treatment planning and an efficient workflow. CT simulation is used to duplicate the radiation-treatment machine in terms of its geometric, mechanical and optical properties by creating a three-dimensional image dataset. This data is then used by the clinicians to localize the tumor and plan treatment without physically having the patient present.

Discovery RT boasts an 80 cm bore with an 80 cm field-of-view, enabled by Max Field of View* (MaxFOV), a new feature of this system. MaxFOV delivers CT images with specified spatial and density values to the edge of the bore — an industry first, according to the company. The large bore and MaxFOV enables the flexibility to position the patients in different treatment positions and then to image the full patient volume for more accurate simulation and therapy planning.

GE Healthcare’s Smart Deviceless 4-D technology delivers workflow efficiency and patient comfort in 4-D motion assessment. Smart Deviceless 4-D provides and displays images of all phases of a breathing cycle, which helps to simplify the motion assessment workflow. Deviceless 4-D assesses motion without an external respiratory gating device, another unique feature of the Discovery RT system designed to improve workflow and patient comfort with no compromise to accuracy and precision.

The Discovery RT combines Smart Deviceless 4-D technology with Smart Metal Artifact Reduction (MAR) to address two of treatment planning’s biggest challenges – the ability to outsmart metal and motion. When utilizing CT scans, clinicians are often challenged by image distortions caused by high-z metals in the body such as hip prosthesis, screws or dental fillings. Metals often generate streak-like artifacts in CT scans, making it difficult to clearly delineate between tumors and healthy tissue. Smart MAR addresses this challenge with a three-stage, projection-based method designed to address both causes of metal artifacts – photon starvation and beam hardening. This automated approach is designed to reveal anatomic details obscured by metal artifacts.

The GE MR Radiation Oncology Suite is another addition to the complete portfolio of radiation oncology solutions from GE Healthcare. The suite includes a full complement of coils, positioning devices and pulse sequences to get voxels the right size in treatment position that can improve accuracy for treatment planning. In addition to the MR (magnetic resonance) oncology suite, the Signa PET/MR, which has been commercially available in the United States since November 2014, offers time-of-flight positron emission tomography (PET) reconstruction with high sensitivity to explore lower PET dose opportunities. The Signa PET/MR is available with MR Silenz, part of SilentScan, with zero TE capability. Zero TE allows development in the area of bone segmentation, which has potential uses for MR simulation.

GE Healthcare also offers ExAblate, an MR-guided focused ultrasound that delivers high intensity focused ultrasound that thermally ablates targeted tissue using MRI to identify and target tumors while providing temperature monitoring of the treated tissue in real time. Also on display at ASTRO, the Discovery PET/CT portfolio features advanced motion management and Q.Clear, an exclusive reconstruction engine that improves up to two times the quantitation accuracy (SUVmean) and image quality (SNR), aimed at a more accurate treatment response assessment.

Discovery RT and MaxFOV are not yet CE marked.

For more information: www.gehealthcare.com

Related Content

BrainLAB Announces FDA Clearance For Two New Indication-Specific Radiosurgery Software Applications
Technology | Treatment Planning | September 21, 2017
Brainlab announced that it has received U.S. Food and Drug Administration (FDA) clearance for Elements Spine SRS and...
Accuray Showcases CyberKnife and Radixact Systems at ASTRO 2017
News | Radiation Therapy | September 21, 2017
Accuray Inc. announced that data and first-hand experience with its advanced CyberKnife and Radixact Systems will be...
RayCare Oncology Information System Being Shown at ASTRO 2017
News | Radiation Therapy | September 20, 2017
RaySearch will be exhibiting its next-generation oncology information system (OIS) RayCare, among other highlights, at...
ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients
News | Proton Therapy | September 20, 2017
ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free milestone for the first...
Varian to Showcase Latest Radiation Therapy Technologies and Software at ASTRO 2017
News | Radiation Therapy | September 19, 2017
Varian Medical Systems announced it will be demonstrating its new Halcyon platform and HyperArc high-definition...
Elekta to Highlight MOSAIQ Oncology Analytics at ASTRO Annual Meeting
News | Radiation Therapy | September 19, 2017
September 19, 2017 — Elekta will highlight its Mosaiq Oncology...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Hitachi Supria True64 CT Receives FDA Clearance
Technology | Computed Tomography (CT) | September 15, 2017
September 15, 2017 — Hitachi Healthcare Americas Inc. announced it has attained U.S.
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Clinical Trials and Cutting-Edge Radiation Oncology Research to Be Featured at ASTRO 2017
News | Radiation Therapy | September 14, 2017
The program for the 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO), Sept. 24-27 in San...
Overlay Init